LONG-TERM PHYSIOLOGIC EFFECTS OF GH IN HIV LIPODYSTROPHY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是评估对艾滋病毒携带者和脂肪分布改变(艾滋病毒脂营养不良综合征)的男性和女性给予生长激素的效果。HIV脂肪营养不良患者的生长激素水平降低，这可能导致腹部脂肪增加，骨密度降低，心血管疾病风险增加，胰岛素敏感性降低。先前对患有生长激素缺乏的非艾滋病毒感染患者的研究表明，低剂量的生长激素改善了身体成分和骨密度，并降低了心血管疾病的风险。在这项研究中，生长激素水平与骨形成、身体成分、心血管风险和胰岛素敏感性的关系将被调查。符合研究入选标准的60名受试者(刺激性生长激素和生长激素水平7.5微克/分升，有脂肪营养不良的证据，无糖尿病病史)将被纳入这项研究，为期三年，共18次访问：筛查访问、10次1小时访问和7天访问。男性和女性都将被录取。参与者将自我注射生长激素18个月，并服用安慰剂(不含有效成分)18个月。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to evaluate the effects of giving growth hormone to men and women with HIV and changes in fat distribution (the HIV lipodystrophy syndrome). Growth hormone levels are reduced in patients with HIV lipodystrophy, and this may result in increased abdominal fat, decreased bone density, increased risk of cardiovascular disease and decreased insulin sensitivity. Prior studies in non-HIV infected patients with growth hormone deficiency have shown that low dose growth hormone improves body composition and bone density, as well as decreasing the risk of cardiovascular disease. In this study, the relationship between growth hormone levels and bone formation, body composition, cardiovascular risk and insulin sensitivity will be investigated. A target of sixty subjects who meet the entrance criteria of the study (stimulated GH <7.5 mcg/dL, evidence of lipodystrophy, no history of diabetes) will be enrolled in this study for three years, with a total of 18 visits: the screening visit, ten one-hour visits, and seven day-long visits. Both male and female subjects will be enrolled. Participants will self-inject growth hormone for 18 months and placebo (contains no active ingredients) for 18 months.